Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Minority Interest (2016 - 2017)

Rein Therapeutics (RNTX) has disclosed Minority Interest for 2 consecutive years, with $130.4 million as the latest value for Q2 2017.

  • Quarterly Minority Interest changed N/A to $130.4 million in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $130.4 million through Jun 2017, changed N/A year-over-year, with the annual reading at $129.7 million for FY2016, 32.83% up from the prior year.
  • Minority Interest for Q2 2017 was $130.4 million at Rein Therapeutics, up from $129.7 million in the prior quarter.
  • The five-year high for Minority Interest was $130.4 million in Q2 2017, with the low at $129.7 million in Q4 2016.